Study of Apatinib in Metastatic Triple-Negative Breast Cancer Patients

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Jiangsu HengRui Medicine Co., Ltd.
Information provided by (Responsible Party):
Xichun Hu, Fudan University
ClinicalTrials.gov Identifier:
NCT01176669
First received: July 20, 2010
Last updated: December 1, 2013
Last verified: December 2013
  Purpose

The hypothesis of this clinical research study is to discover if the study drug apatinib can shrink or slow the growth of pretreated metastatic triple-negative breast cancer.


Condition Intervention Phase
Metastatic Breast Cancer
Drug: Apatinib
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Single-Institutional Phase IIa Trial and A Multi-Institutional Phase IIb Trial of Apatinib in Metastatic Triple-Negative Breast Cancer

Resource links provided by NLM:


Further study details as provided by Fudan University:

Primary Outcome Measures:
  • DCR(Disease control rate) for IIa [ Time Frame: 8 Weeks ] [ Designated as safety issue: Yes ]
  • PFS(Progression free survival) for IIb [ Time Frame: 8 Weeks ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • PFS(Progression free survival) for IIa [ Time Frame: 8 Weeks ] [ Designated as safety issue: Yes ]
  • OS (Overall survival) [ Time Frame: 8 Weeks ] [ Designated as safety issue: Yes ]
  • ORR (Objective response rate) [ Time Frame: 8 Weeks ] [ Designated as safety issue: Yes ]
  • Number of Participants with Adverse Events as a Measure of Safety and Tolerability [ Time Frame: 8 weeks ] [ Designated as safety issue: Yes ]
  • QoL (Quality of life) [ Time Frame: 8 Weeks ] [ Designated as safety issue: Yes ]
  • DCR(Disease control rate) for IIb [ Time Frame: 8 Weeks ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 60
Study Start Date: June 2010
Estimated Study Completion Date: June 2015
Estimated Primary Completion Date: August 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Apatinib Drug: Apatinib
Apatinib was administratered at 750 mg/d in Phase IIa. The actual average dose intensity delivered was 525 mg/d due to toxicities. So, in Phase IIb, the starting dose of apatinib will be 500mg/d. Two dose reductions will be allowed to 375 and then 250 mg/d.
Other Name: Target therapy

Detailed Description:

Apatinib is a tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor (VEGFR), and its anti-angiogenesis effect has been viewed in preclinical tests. The investigators' phase I study has shown that the drug's toxicity is manageable and the maximum tolerable daily dose is 850 mg. The hypothesis of this clinical research study is to discover if the study drug apatinib can shrink or slow the growth of triple-negative breast cancer. The safety of apatinib will also be studied. Patients physical state, symptoms, changes in the size of the tumor, and laboratory findings obtained while on-study will help the research team decide if apatinib is safe and effective in pretreated metastatic triple-negative breast cancer patients.

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • ≥ 18 and ≤ 70 years of age.
  • ECOG performance status of 0-1.
  • Women diagnosed with triple negative breast cancer (breast cancer is estrogen receptor negative (ER-), progesterone receptor negative (PgR-) and human epidermal growth factor receptor negative (HER2-). HER2- is defined as 0 or 1+ staining on immunohistochemistry or FISH/CISH negative for gene amplification.
  • Metastatic breast cancer, confirmed by histological analysis.
  • Have failed for at least one chemotherapy regimen, but at most three regimens(including adjuvant and neo-adjuvant setting).
  • Duration from the last therapy (chemotherapy, radiotherapy, target therapy and operation) is more than 4 weeks (Duration for nitroso or mitomycin is 6 weeks).
  • Have at least one extracranial measurable site of disease according to RECIST 1.1 criteria that has not been previously irradiated. If the patient has had previous radiation to the marker lesion(s), there must be evidence of disease progression since the radiation.
  • Life expectancy of more than 3 months.
  • If the patients have brain or meninges metastases, the lesions must have been controlled at least 8 weeks.
  • Adequate hepatic, renal, heart, and hematologic functions (hemoglobin ≥ 9.0g/dl, neutrophils ≥ 1.5×10^9/L, platelets ≥ 80×10^9/L , ALT ≤ 2.5 x upper limit of normal (ULN), AST ≤ 2.5 x ULN, serum bilirubin ≤ 1.5 x ULN, serum creatine ≤ 1.5 x ULN, creatinine clearance rate ≥ 50ml/min, PT, APTT, TT, Fbg normal).
  • Written informed consent prior to study specific screening procedures, with the understanding that the patient has the right to withdraw from the study at any time without prejudice.

Exclusion Criteria:

  • Pregnant or lactating women.
  • Less than 4 weeks from the last clinical trial.
  • Have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study such as: Congestive heart failure: New York Heart Association Class III/IV, Unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction within 6 months of start of study drug, serious uncontrolled cardiac arrhythmia or any other clinically significant cardiac disease.
  • Any factors that influence the usage of oral administration.
  • Receiving the therapy of thrombolysis or anticoagulation.
  • Unhealed wound or bone fracture.
  • Urine protein ≥++ and confirmed >1.0 g by the 24h quantity.
  • Previous or present history of pulmonary fibrosis,interstitial pneumonia,pneumoconiosis,radiation pneumonitis,drug-related pneumonitis or greatly-impaired pulmonary function.
  • Disability of serious uncontrolled intercurrence infection.
  • Abuse of alcohol or drugs.
  • Have received prior treatment with a VEGFR, PDGFR or s-SRC TKI (Bevacizumab is permitted).
  • History of other malignancies except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01176669

Locations
China, Shanghai
Fudan University Cancer Hospital
Shanghai, Shanghai, China, 200032
Sponsors and Collaborators
Fudan University
Jiangsu HengRui Medicine Co., Ltd.
Investigators
Study Chair: Xichun Hu, Doctorship Fudan University
  More Information

No publications provided by Fudan University

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Xichun Hu, Professor, Fudan University
ClinicalTrials.gov Identifier: NCT01176669     History of Changes
Other Study ID Numbers: Fudan BR2010-03
Study First Received: July 20, 2010
Last Updated: December 1, 2013
Health Authority: China: Food and Drug Administration

Keywords provided by Fudan University:
Apatinib
Triple-Negative Breast Cancer
Metastatic Breast Cancer
ER/PR Negative
Her2/Neu Negative

Additional relevant MeSH terms:
Breast Neoplasms
Triple Negative Breast Neoplasms
Breast Diseases
Neoplasms
Neoplasms by Site
Skin Diseases

ClinicalTrials.gov processed this record on October 23, 2014